Conference Call with OneSource Specialty Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company OneSource Specialty Pharma announced Q2FY26 results Revenues at Rs 3,758 million, up 12% YoY. EBITDA grew 37% YoY to Rs 1,065 million. EBITDA margin of 28%, an expansion of ~506 bps YoY. Adjusted PAT stood at Rs 449 million with adjusted EPS of Rs 3.9. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: “Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to USD 500 million+.” Result PDF
Conference Call with OneSource Specialty Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company OneSource Specialty Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue: for Q4FY25 Rs 4,260 million, up 22% YoY. EBITDA grew 79% YoY 1,825 million during Q4FY25. Q4FY25 EBITDA margin of 43%, an expansion of 1,362 basis points YoY Q4FY25 PAT stood at Rs 992 million with adjusted EPS of Rs 12.2. FY25 Financial Highlights: Revenue: for FY25 Rs 14,449 million, up 30% YoY. FY25 EBITDA grew 104% YoY 4,665 million. FY25 EBITDA margin of 32%, a YoY expansion of 1,165 basis points. FY25 PAT Rs 9361 million adjusted for one-time exceptional items. 39 new RFPs/ licensing deals won with ~50% coming from existing customers. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma,said: "We're delighted to announce 30% revenue increase, driven by all-round robust growth. EBITDA grew significantly due to product mix in favour of Drug Device Combinations (DDCs) and Biologics, and higher operational efficiencies. Our business has been driven by strong customer acquisition and new MSAs. With the successful on-going integration of the acquired entities, we're achieving cross-selling opportunities, and cost synergies, creating greater value for customers and shareholders." Result PDF
Conference Call with OneSource Specialty Pharma Management and Analysts on Q4FY25 & FY25 Performance and Outlook. Listen to the full earnings transcript.